Supreme Court Questions High Cancer Drug Markups, Seeks Uniform Pricing Cap
The Supreme Court has raised concerns over steep markups on cancer drugs, highlighting cases where medicines costing retailers around Rs 2,700 are sold to patients at MRPs up to Rs 27,000. The court questioned the absence of uniform price controls under the Drugs (Prices Control) Order, 2013, and the practice of hospitals mandating purchases from in-house pharmacies. It urged the Centre to consider a uniform 16 percent margin cap on all medicines to reduce patient and taxpayer burdens. Karnataka's government also sought central intervention to regulate high-value drug prices and trade margins.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. Coverage leans balanced overall (Left 11%, Centre 89%, Right 0%). Overall sentiment is negative (36/100). Lens Score 63/100.
Outlets measured: deccanherald, hindustantimes, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 2 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (28–42/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 27 Sept, 04:17 pm. Other outlets followed.